XFOR Stock Analysis: Buy, Sell, or Hold?
XFOR - X4 Pharmaceuticals, Inc. Common Stock
$4.04
0.00 (0.00%)
▲
5d:
+0.0%
30d:
-3.12%
90d:
+5.48%
HOLD
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Aug 14, 2026
0d
Get Alerted When XFOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: XFOR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: XFOR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: XFOR is currently trading at $4.04, which is considered slightly low relative to its 30-day fair value range of $3.99 to $4.28.
Technical Outlook: Technically, XFOR is showing sideways momentum. The price is currently testing key support at $3.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: XFOR scores 67/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Implied Volatility is high (74th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $11.60 (+187.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, XFOR is showing sideways momentum. The price is currently testing key support at $3.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: XFOR scores 67/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Implied Volatility is high (74th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $11.60 (+187.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.99 -
$4.28
Company Quality Score
57/100
(HOLD)
Options IV Signal
74th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
75.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 74th percentile)
- BULLISH: Strong technical setup (67/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 187.1% below Wall St target ($11.60)
- CAUTION: Bottoming setup, but lagging the sector by 10% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$3.99 -
$4.28
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$2.00
(49.4%)
Support & Resistance Levels
Support Level
$3.94
Resistance Level
$4.39
Current Trend
Sideways
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.35
Wall Street Target
$11.60
(+187.1%)
Revenue Growth (YoY)
346.3%
Share & Embed Analysis
Last updated: September 04, 2026 10:53 PM ET
Data refreshes hourly during market hours. Next update: 11:53 PM
Data refreshes hourly during market hours. Next update: 11:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XFOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 46 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1176 | 44 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 27 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$133 | 51 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
